Brought to you by 
Sanofi gets rights to Lexicon's oral diabetes project sotagliflozin; approval troubles ensue, deal ends
11 Sep 2019
Executive Summary
In its second diabetes deal announced in as many days, Sanofi licensed exclusive global rights to develop and sell Lexicon Pharmaceuticals Inc.'s oral Type I and Type II diabetes candidate sotagliflozin (LX4211).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sanofi gets rights to Lexicon's oral diabetes project sotagliflozin; approval troubles ensue, deal ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice